Ticker Symbol: EQ
Equillium Inc
$5.46 - 20-12-2024 4 p.m. ET
Exchange: NASDAQ
Country:
US
Currency:
USD
Asset
Type: Common Stock
CIK:0001746466
Company Profile
Equillium is a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to treat severe autoimmune and inflammatory disorders with high unmet medical need. Equillium is developing itolizumab for multiple severe immuno-inflammatory diseases, including acute graft-versus-host-disease (aGVHD), lupus/lupus nephritis and uncontrolled asthma.
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Standard Industrial Classification Code (SIC code): 2834
Address: 2223 Avenida de La Playa Ste 105
Website: equilliumbio.com
CEO: Bruce Steel
Tags:
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Pricing
Last Updated: October 3, 2023 03:00 PM EST
Previous Close: $0.72
Change:
$0.00
(
-0.54%)
Days Range: $0.71 - $0.76
Beta: 1.07
52wk. High: $1.97
52wk. Low: $0.47
Ytd. Change -32.15%
50 Day Moving Average: $0.74
200 Day Moving Average: $0.72
Shares Outstanding: 34568500
Valuation
Market Cap: 2.5B
PE Ratio: -
EPS (TTM): 0
Dividends
Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A